Newsbenzinga
Lexeo Therapeutics Says FDA Grants RMAT Designation To LX2020 Gene Therapy For PKP2-ACM Based On Interim Phase I/II HEROIC-PKP2 Data
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…